Abstract
Many studies have shown that the lysosomal cathepsins, especially cathepsins B/L (CTSB/L) are required for SARS-CoV-2 entry into host cells. Lysosomal proteases, cathepsins are indispensable for normal health and are involved in several brain disorders occurring at different development age periods. On the other hand, it has been well known that COVID-19 infection is largely associated with several neurological disorders. Taken together these findings and given the high levels of expression of CTSB/L in the brain, we here proposed a reasonable hypothesis about the involvement of CTSB/L in the neurological manifestations linked to COVID-19. Pharmacological inhibitions of the CTSB/L could be a potential therapeutic target to block the virus entry as well as to mitigate the brain disorders. To this end, we utilized the network-based drug repurposing analyses to identify the possible drugs that can target CTSB/L. This study identifies the molecules like cyclosporine, phenytoin, and paclitaxel as potential drugs with binding ability to the CTSB/L. Further, we have performed molecular docking and all-atom molecular dynamics (MD) simulations to investigate the stability of CTSL-drug complexes. The results showed strong and stable binding of drugs with CTSL.
【저자키워드】 COVID-19, Drug repurposing, SARS-CoV-2, neurological manifestations, cyclosporine, Cathepsins, 【초록키워드】 molecular docking, drug, Brain, CTSL, Health, stability, COVID-19 infection, virus entry, age, Proteases, molecular, Neurological disorders, expression, binding, cathepsin, Hypothesis, host cells, Complexes, disorders, SARS-CoV-2 entry, disorder, potential therapeutic target, binding ability, neurological manifestation, mitigate, lysosomal cathepsins, shown, identify, performed, involved, required, analysis, 【제목키워드】 targeting, neurological manifestation,